Straits Times Index
3,309.21 -12.87 (-0.39%) S&P 500
5,336.12 -24.67 (-0.46%) Dow
38,544.12 -323.92 (-0.83%) Nasdaq
17,158.77 -33.76 (-0.20%) Bitcoin USD
66,918.37 -2,518.72 (-3.63%) CMC Crypto 200
1,388.14 -53.49 (-3.71%)
BIIB Jan 2025 185.000 call
| Previous close | 50.96 |
| Open | 51.79 |
| Bid | 50.70 |
| Ask | 56.50 |
| Strike | 185.00 |
| Expiry date | 2025-01-17 |
| Day's range | 50.96 - 51.79 |
| Contract range | N/A |
| Volume | |
| Open interest | 128 |
Yahoo FinanceFDA panel votes unanimously for Eli Lilly's Alzheimer's treatment
An FDA panel voted unanimously to support Eli Lilly's Alzheimer's drug for use in adults 60-85 years old.
ZacksBiogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025.
GlobeNewswireFDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. A Prescription Drug Us
